Roche's Gazyvaro set for EU approval
This article was originally published in Scrip
Executive Summary
Roche's anti-CD20 monoclonal antibody product obinutuzumab has been granted a positive opinion for marketing as Gazyvaro in chronic lymphocytic leukemia (CLL), at the CHMP's latest meeting this week.